Comparison
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532 vs 17p11 2 Microduplication Syndrome C2931246
Clinical comparison between 3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency and 17p11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
A metabolic disorder affecting the body's ability to produce energy from fats. Episodes of low blood sugar, vomiting, and metabolic crisis can occur, especially during fasting or illness. Dietary management and emergency protocols are essential.
17p11 2 Microduplication Syndrome C2931246
A chromosomal condition involving duplication on chromosome 17, related to Potocki-Lupski syndrome. Features often include developmental delays, learning challenges, and distinctive facial features.
6 comparison axes
Onset
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
0-6
17p11 2 Microduplication Syndrome C2931246
0-null
Onset patterns differ
Severity
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
severe
17p11 2 Microduplication Syndrome C2931246
moderate
Different severity levels
Chronic
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
Chronic
17p11 2 Microduplication Syndrome C2931246
Chronic
Differing course
Communicable
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
No
17p11 2 Microduplication Syndrome C2931246
No
Different transmission
Body System
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
metabolic
17p11 2 Microduplication Syndrome C2931246
congenital
Same/different system
Category
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
metabolic
17p11 2 Microduplication Syndrome C2931246
genetic
Different category
Bottom line
3-hydroxy-3-methylglutaryl-coa-synthase-deficiency-C2751532 and 17p11-2-microduplication-syndrome-C2931246 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532 | 17p11 2 Microduplication Syndrome C2931246 | Discriminating power |
|---|---|---|---|
| Metabolic crisis | Hypoglycemia, vomiting, lethargy, especially with fasting or illness | Not a typical presenting feature | High |
| Development | Usually not the primary phenotype; neurologic injury may follow severe crises | Developmental delay, learning difficulty, and hypotonia are common | High |
| Facial features | No characteristic facial pattern is established | Distinctive facial features may be present | Moderate |
When to favor each condition
Choose 3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532 when
Infant or child with fasting-related hypoglycemia and vomiting
Fits a disorder of ketogenesis rather than a chromosomal developmental syndrome
High
Illness triggers encephalopathy or metabolic decompensation
Acute energy failure is characteristic and needs urgent metabolic evaluation
High
Abnormal organic-acid or acylcarnitine pattern without dysmorphic features
Supports targeted metabolic and genetic testing; a result alone is not a diagnosis
Moderate
Choose 17p11 2 Microduplication Syndrome C2931246 when
Congenital developmental delay with learning challenges
Phenotype aligns with 17p11.2 microduplication, including Potocki-Lupski syndrome
High
Dysmorphic features without episodic hypoglycemia
Chromosomal microarray is more relevant than acute metabolic testing
Moderate
Family or prenatal concern for a copy-number variant
Diagnosis depends on detecting the duplication, interpreted by a genetics clinician
High
How key tests differ
| Test | 3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532 | 17p11 2 Microduplication Syndrome C2931246 | Interpretation |
|---|---|---|---|
| Glucose and ketones during illness | Hypoketotic hypoglycemia may occur | No specific metabolic pattern expected | Suggestive only; confirm with specialist metabolic testing |
| Urine organic acids or plasma acylcarnitines | May show a ketogenesis-related pattern | Usually not diagnostic | Abnormal results require laboratory and clinician correlation |
| Chromosomal microarray | Not expected to identify this enzyme disorder | May detect 17p11.2 duplication | Genetic confirmation needs expert interpretation and counseling |
Prognosis comparison
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
- Outcome
- Often manageable with diet and emergency plans, but crises can be serious
- Factors
- Fasting, intercurrent illness, and delayed treatment
17p11 2 Microduplication Syndrome C2931246
- Outcome
- Generally a chronic developmental condition of moderate severity
- Factors
- Duplication extent, associated features, and access to support
Time frame: Lifelong, with early childhood often most critical
Neither prognosis nor mortality can be quantified from the supplied data
Complications comparison
| Complication | Presentation |
|---|---|
| Acute decompensation | Can cause severe hypoglycemia and encephalopathy Not the usual course Emergency protocols are essential for the metabolic disorder |
| Neurodevelopment | Risk mainly after severe or recurrent crises Developmental and learning challenges are central Support needs differ and should be individualized |
| Feeding or growth issues | Fasting intolerance and illness management dominate Feeding difficulty or hypotonia may occur Exact frequency is not established here |
Patient education highlights
- HighEmergency care
For HMG-CoA synthase deficiency, avoid prolonged fasting and seek urgent care for vomiting, lethargy, or illness.
- HighCorrect diagnosis
These conditions have different causes; genetic or metabolic results should be explained by a clinician.
- MediumDevelopmental support
Children with 17p11.2 microduplication may benefit from early therapy and educational support.